Protocol: PK Bridging ELISA for Use with Anti-Belimumab Antibodies

Protocol: PK Bridging ELISA for Use with Anti-Belimumab Antibodies

Protocol: PK Bridging ELISA for Use with Anti-Belimumab Antibodies

Protocol: PK Bridging ELISA for Use with Anti-Belimumab Antibodies

Download PDF

Pharmacokinetic (PK) Bridging ELISA: For Use with Anti-Belimumab Monoclonal Antibodies Catalog TZA0101 and TZA0102/TZA0102P

This method provides a procedure for carrying out a PK ELISA with Anti-Belimumab Antibodies, TZA0101 (capture antibody) and HRP-conjugated TZA0102/TZA0102P (detection antibody), using belimumab for the standard curve. The method should always be used in conjunction with product and batch-specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.

Reagents

BSA (Sigma-Aldrich, A7906)
HISPEC Assay Diluent (BUF049)
Human Serum (Sigma-Aldrich, H4522)
Phosphate buffered saline (PBS)
136 mM NaCl
2.68 mM KCl
8.1 mM Na2HPO4
1.46 mM KH2PO4
PBST
PBS with 0.05% Tween 20 (Merck Millipore, 817072)
QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher Scientific, 15169)

Materials

384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, 10395991)
Fluorescence plate reader
96-well plates can be used instead of 384-well plates (black, flat-bottom wells), for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, 437111). For the 96-well format, use 100 μL (instead of 20 μL) of antigen, antibodies, or substrate and 300 μL for the blocking step.

Method

  1. If using TZA0102P (AbD59897pap) for detection, proceed to step 2. If using TZA0102 (AbD59897ad) for detection, prepare the detection anti-belimumab antibody: couple TZA0102 (AbD59897ad) to a suitable SpyCatcher Reagent (e.g., TZC002P) using the (Bi)SpyCatcher coupling protocol.
  2. Prepare the capture Anti-Belimumab Antibody TZA0101 (AbD59900ad) at 1 µg/mL in PBS. Coat the required number of wells of a 384-well microtiter plate with 20 µL per well of the prepared capture antibody, and incubate overnight at 4°C.
  3. Wash the microtiter plate five times (5x) with PBST.
  4. Block the microtiter plate by adding 100 µL 5% BSA in PBST to each well, and then incubate for 1 hr at RT.
  5. Wash the microtiter plate 5x with PBST.
  6. For the standard curve, prepare a dilution series of belimumab in 10% human serum in PBST in triplicate. Final concentration of belimumab should cover the range from 0.3 ng/mL to 30,000 ng/mL. Include a zero belimumab concentration as the background value.
  7. Add 20 µL of belimumab dilution per well (in triplicate for each standard recommended). Add 20 µL of each test sample to the other wells (in triplicate for each sample recommended). Incubate for 1 hr at RT.
  8. Wash the microtiter plate 5x with PBST.
  9. To each well, add 20 µL HRP-conjugated detection Anti-Belimumab Antibody, TZA0102 (AbD59897ad)/TZA0102P (AbD59897pap) at 0.5 µg/mL in HISPEC Assay Diluent. Incubate for 1 hr at RT.
  10. Wash the microtiter plate 10x with PBST.
  11. Add 20 µL QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.